Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.

MLA

Lee, Lauren J., et al. “Improved Survival Outcomes with the Addition of Rituximab to Initial Therapy for Chronic Lymphocytic Leukemia: A Comparative Effectiveness Analysis in the Province of British Columbia, Canada.” Leukemia & Lymphoma, vol. 59, no. 6, June 2018, pp. 1356–63. EBSCOhost, https://doi.org/10.1080/10428194.2017.1387904.

APA

Lee, L. J., Toze, C. L., Huang, S. J. T., Gillan, T. L., Connors, J. M., Sehn, L. H., Bruyere, H., Leitch, H., Ramadan, K. M., & Gerrie, A. S. (2018). Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada. Leukemia & Lymphoma, 59(6), 1356–1363. https://doi.org/10.1080/10428194.2017.1387904

Chicago

Lee, Lauren J., Cynthia L. Toze, Steven J. T. Huang, Tanya L. Gillan, Joseph M. Connors, Laurie H. Sehn, Helene Bruyere, Heather Leitch, Khaled M. Ramadan, and Alina S. Gerrie. 2018. “Improved Survival Outcomes with the Addition of Rituximab to Initial Therapy for Chronic Lymphocytic Leukemia: A Comparative Effectiveness Analysis in the Province of British Columbia, Canada.” Leukemia & Lymphoma 59 (6): 1356–63. doi:10.1080/10428194.2017.1387904.